The granulocyte colony-stimulating factor (G-CSF)/ATG-based Beijing protocol was one of the most commonly used regimens after haplo-HSCT because it has a stronger graft-versus-leukemia (GVL) effect among certain patients at high risk of relapse, with outcomes at least comparable to HLA-matched sibling donor transplantation (MSDT) (15). The gene discussed is CSF3; the disease is leukemia.